Medical Marijuana for Spasticity in Ohio

Spasticity is one of Ohio’s recognized standalone qualifying conditions for medical marijuana — listed by name in Ohio law separately from the specific conditions that most commonly cause it, such as multiple sclerosis and spinal cord injury. This means Ohio patients experiencing spasticity from any neurological cause may qualify for the program — not just those with MS or SCI diagnoses. This page explains how spasticity qualifies, what the research shows, and how to approach the evaluation.

Does Spasticity Qualify for Medical Marijuana in Ohio?

Yes. Spasticity is explicitly listed as a qualifying condition under Ohio Revised Code Section 3796.01 and recognized by name on the State Medical Board of Ohio’s covered conditions page.

Critically — spasticity qualifies as its own standalone condition in Ohio law. This means patients with spasticity from cerebral palsy, traumatic brain injury, stroke, spinal cord injury, multiple sclerosis, or any other neurological cause may qualify under the spasticity category — even if their underlying condition is not separately listed. A physician holding a Certificate to Recommend (CTR) evaluates whether your documented spasticity and symptom picture support a medical marijuana recommendation.

What Is Spasticity and What Causes It?

Spasticity is a condition characterized by abnormal muscle tone — involuntary muscle stiffness, tightness, and spasms — resulting from damage or dysfunction of the central nervous system. It occurs when the normal inhibitory signals from the brain or spinal cord to the muscles are disrupted, leading to muscles that are persistently activated or hyper-responsive.

Common causes of spasticity in Ohio patients include:

• Multiple sclerosis — spasticity is one of MS’s most disabling symptoms
• Spinal cord injury — from trauma or disease
• Traumatic brain injury
• Stroke
• Cerebral palsy
• Neurodegenerative conditions

Spasticity causes significant impairment in mobility, daily function, sleep, and quality of life — and conventional treatments including baclofen, tizanidine, dantrolene, and benzodiazepines have limited effectiveness and significant side effect burdens for many patients.

What Does the Research Show About Cannabinoids and Spasticity?

Spasticity — particularly neurological spasticity from MS and spinal cord injury — has one of the strongest evidence bases of any condition for cannabinoid therapy.

The Highest-Level Evidence for Cannabinoids in Any Neurological Condition

As noted in a comprehensive review published through PMC, the only use of cannabinoids in neurological disorders with high-level evidence for efficacy is pharmaceutical cannabinoids for spasticity — specifically in MS. This is an important statement from the research community — spasticity represents the gold standard indication for cannabinoid therapy in neurology.

A 2015 research review published in the Journal of the American Medical Association examining more than 20 randomized clinical trials of cannabinoids found that use of marijuana for spasticity due to multiple sclerosis is supported by high-quality evidence — one of the strongest endorsements of cannabis in any medical context.

Controlled Trial Evidence

A randomized controlled trial published through PMC examining cannabinoids in MS-associated spasticity found that 61% of patients on cannabis extract and 60% on THC reported improvement in spasticity — compared to 46% on placebo. Patient-reported spasticity and pain improvement reached statistical significance.

A study of inhaled cannabis versus placebo in MS patients with spasticity found that patients on cannabis reduced their spasticity score on the modified Ashworth Scale by an average of 2.74 points more than placebo — alongside a 5.28 point average reduction in pain scores.

A longitudinal study published through PubMed examining medicinal cannabis specifically for patients with muscle spasticity or spasms found differential benefits across cannabis product types — with CBD-only formulations improving sleep disturbance, fatigue, pain interference, and pain intensity in spasticity patients, while THC-containing or balanced products benefited those with spasms across the same four outcomes.

The Patient-Reported vs Objective Measurement Gap

A consistent pattern in spasticity research is that patient-reported improvements are more reliably documented than objective clinician-measured spasticity improvements on scales like the Ashworth Scale. As noted in the PMC review, while multiple systematic reviews report conclusive evidence that oral cannabinoids improve patient-reported MS spasticity, the effects on objective clinician-measured spasticity measures are more modest and less consistent.

This does not diminish the clinical value of patient-reported improvement — for patients whose quality of life and daily function are significantly affected by spasticity, subjective relief is itself a meaningful outcome.

Why Spasticity Qualifies Separately From MS and SCI in Ohio

Ohio’s decision to list spasticity as its own qualifying condition — separate from MS and spinal cord injury — has important practical implications for patients.

A patient with cerebral palsy, stroke-related spasticity, or TBI-related spasticity may not qualify under the MS or spinal cord injury categories — but can qualify under spasticity itself. Similarly, a patient whose underlying neurological condition is not specifically listed in Ohio law may still qualify through the spasticity category if spasticity is a documented symptom of their condition.

Our condition pages for multiple sclerosis and spinal cord disease or injury cover the research specific to those conditions in detail — including the spasticity evidence base within those populations. This page covers spasticity as a standalone qualifying pathway for patients whose cause of spasticity differs from those specific conditions.

What Documentation Do Ohio Spasticity Patients Need?

Ohio-certified physicians evaluating spasticity patients look for documentation that establishes the diagnosis and underlying cause:

Neurologist or specialist records confirming your spasticity diagnosis and its neurological cause are the most important documents. Records showing antispasticity medications tried — baclofen, tizanidine, dantrolene, benzodiazepines — and their outcomes establish the treatment history context. Symptom documentation noting how spasticity affects your mobility, daily functioning, sleep, and quality of life helps the physician understand the clinical burden. Current medication list for the OARRS check — particularly important as cannabinoids may interact with baclofen and benzodiazepines through CNS depressant effects.

Getting Your Ohio Spasticity Medical Marijuana Evaluation

Ohio’s telemedicine evaluation is completed entirely online — particularly beneficial for spasticity patients whose mobility limitations make in-person clinic visits physically demanding. After completing a short intake form, a brief 10 to 20 minute video consultation with an Ohio-certified physician covers your spasticity diagnosis, neurological history, antispasticity treatment history, and current medications. If approved, your recommendation is submitted to the Ohio Patient & Caregiver Registry and your digital card is activated via email — valid at any licensed Ohio dispensary statewide. There is no charge if the physician determines you do not qualify.

If you are an Ohio spasticity patient and want to find out whether you qualify for the medical marijuana program, you can schedule your evaluation here.

Frequently Asked Questions

Sources

• Ohio Revised Code Section 3796.01 — Qualifying Medical Conditions — Ohio Laws
• State Medical Board of Ohio — Covered Conditions — med.ohio.gov
• Ohio Patient & Caregiver Registry — Ohio Division of Cannabis Control
• The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms — PMC / NIH
• Cannabinoids in the Management of Spasticity Associated with MS — PMC / NIH
• Investigating the Effectiveness of Medicinal Cannabis for Spasticity or Spasms — PubMed